Investigating Chemotherapy Induced Peripheral Neuropathy in Ovarian Cancer Patients
DOI:
https://doi.org/10.58445/rars.450Keywords:
Ovarian Cancer, Chemotherapy-induced peripheral neuropathy, CIPN, Adult, Female, Middle-Aged, Ovarian Neoplasms, Drug/TB therapy, QoL, Chemotherapy drugsAbstract
A woman’s risk of developing ovarian cancer in her lifetime is 1 in 78. Ovarian cancer is characterized by rapid cell growth in or around the ovaries that can compromise healthy tissues. Its subtle early symptoms often delay diagnosis until advanced stages. Chemotherapy, combined with surgery, is a common treatment approach. However, it introduces chemotherapy-induced peripheral neuropathy (CIPN). This neuropathy arises from chemotherapy's impact on peripheral nerves, resulting in sensations like tingling, burning, and weakness. CIPN has profound physical and psychological effects, affecting patients' daily lives and diminishing their quality of life (QoL). This article provides an in-depth exploration of ovarian cancer, its treatments, CIPN's mechanisms, diagnosis, management, and its impact on QoL based on research studies. Two studies highlight CIPN's prevalence among ovarian cancer patients and its detrimental effects on their QoL. Future directions in CIPN management emphasize patient-centered care and further research to alleviate this treatment-induced challenge.
References
Bell, Debra A. “Origins and Molecular Pathology of Ovarian Cancer.” Nature News, Nature Publishing Group, 17 Feb. 2005, www.nature.com/articles/3800306.
“Chemotherapy for Ovarian Cancer: Intraperitoneal Chemotherapy.” Intraperitoneal Chemotherapy | American Cancer Society, 11 Apr. 2018, www.cancer.org/cancer/types/ovarian-cancer/treating/chemotherapy.html.
Desforges, Allison D., et al. “Treatment and Diagnosis of Chemotherapy-Induced Peripheral Neuropathy: An Update.” Biomedicine & Pharmacotherapy, Elsevier Masson, 29 Jan. 2022, www.sciencedirect.com/science/article/pii/S0753332222000592?__cf_chl_tk=u6LbSeZoR02_BPKElslgmbH2kmM4mUvE_vGw5gmZv.s-1692502486-0-gaNycGzNEGU.
Jin, Lin et al. “Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics vol. 149,3 (2020): 303-308. doi:10.1002/ijgo.13137
Maihöfner, Christian, et al. “Chemotherapy-Induced Peripheral Neuropathy (CIPN): Current Therapies and Topical Treatment Option with High-Concentration Capsaicin.” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, U.S. National Library of Medicine, Aug. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8236465/.
Mun, Sohee, and Hyojung Park. “The impact of peripheral neuropathy symptoms, self-care ability, and disturbances to daily life on quality of life among gynecological cancer patients undergoing chemotherapy: a cross-sectional survey.” Korean journal of women health nursing vol. 28,4 (2022): 296-306. doi:10.4069/kjwhn.2022.11.21
“Ovarian Cancer.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 9 May 2023, www.mayoclinic.org/diseases-conditions/ovarian-cancer/symptoms-causes/syc-20375941.
“Ovarian Cancer.” Weill Cornell Medicine, weillcornell.org/services/obstetrics-and-gynecology/gynecologic-oncology/conditions-we-treat/ovarian-cancer. Accessed 20 Aug. 2023.
“What Is Ovarian Cancer: Ovarian Tumors and Cysts.” What Is Ovarian Cancer | Ovarian Tumors and Cysts | American Cancer Society, www.cancer.org/cancer/types/ovarian-cancer/about/what-is-ovarian-cancer.html. Accessed 20 Aug. 2023.
“What Is Peripheral Neuropathy?: Cancer-Related Side Effects.” American Cancer Society, 1 Nov. 2019, www.cancer.org/cancer/managing-cancer/side-effects/nervous-system/peripheral-neuropathy/what-is-peripherial-neuropathy.html.
Downloads
Posted
Categories
License
Copyright (c) 2023 Jasmine Mudhar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license
